Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes
(MEMPHIS, Tenn. – Sept. 24, 2024) – Clinical trial results from St. Jude Children’s Research Hospital demonstrate benefits to using genomics and early treatment response to guide risk classification of children with B-cell acute lymphoblastic leukemia (B-ALL). Traditionally, the intensity of a patient’s chemotherapy regime is guided by the National Cancer Institute (NCI) risk classification, which is largely determined by clinical characteristics such as age and white blood cell count at presentation. Through the flagship St. Jude ...










